Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Free Cash Flow (2022 - 2025)

Zentalis Pharmaceuticals has reported Free Cash Flow over the past 4 years, most recently at -$30.9 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$30.9 million for Q4 2025, up 22.07% from a year ago — trailing twelve months through Dec 2025 was -$125.2 million (up 26.79% YoY), and the annual figure for FY2025 was -$125.2 million, up 26.79%.
  • Free Cash Flow for Q4 2025 was -$30.9 million at Zentalis Pharmaceuticals, down from -$27.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for ZNTL hit a ceiling of -$27.0 million in Q3 2025 and a floor of -$79.6 million in Q2 2023.
  • Median Free Cash Flow over the past 4 years was -$39.2 million (2023), compared with a mean of -$41.9 million.
  • Biggest five-year swings in Free Cash Flow: crashed 85.57% in 2023 and later surged 55.62% in 2024.
  • Zentalis Pharmaceuticals' Free Cash Flow stood at -$37.5 million in 2022, then decreased by 8.76% to -$40.8 million in 2023, then grew by 2.62% to -$39.7 million in 2024, then increased by 22.07% to -$30.9 million in 2025.
  • The last three reported values for Free Cash Flow were -$30.9 million (Q4 2025), -$27.0 million (Q3 2025), and -$34.7 million (Q2 2025) per Business Quant data.